[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517526":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":30,"locations":29,"responsibleParty":36,"collaborators":29,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":29,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":29,"enrollmentInfo":49,"targetDuration":29,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":63,"whyStopped":29,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":29},{"fullName":5,"class":6},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"osimertinib and aspirin","EXPERIMENTAL","Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals.The participants will undergo a two-month combination therapy, unless there is tumor progression (worsening) or intolerable toxic reactions that necessitate early termination of the drug treatment. Aspirin will be discontinued one week prior to the surgery.",[13,14],"Drug: Osimertinib","Drug: Aspirin",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Osimertinib","Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.",[9],[22],"OSI",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Aspirin","Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.",[9],[28],"ASP",null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"He yong","CONTACT","86-23-68757791","heyong8998@126.com",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Yong He","Professor","100517526","phase-2-osimertinib-combined-with-aspirin-neoadjuvant-therapy-for-resectable-egfr-mutated-nsclc-patients-100517526",false,"NCT06018688","Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.","A Phase II Study Evaluating Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated Non-small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Patients with resectable stage IIA-IIIA lung adenocarcinoma.\n2. Patients with EGFR sensitizing mutations (Ex19del or L858R).\n3. Intended neoadjuvant therapy with osimertinib, with an anticipated survival expectancy of more than 3 months.\n4. ECOG PS 0\u002F1.\n5. Primary lesion diameter of at least 1 cm.\n6. Patients who have previously taken or are currently taking aspirin therapy are allowed.\n\nExclusion Criteria:\n\n1. Currently receiving other anticoagulant therapy.\n2. Previously treated with systemic therapy for NSCLC.\n3. Other positive driver mutations, including ALK, ROS1, MET14 exon skipping, BRAF, RET, etc.\n4. Contraindications to the use of osimertinib and aspirin.","ALL","18 Years",{"count":50,"type":51},44,"ESTIMATED","INTERVENTIONAL",[54],"PHASE2","This is a single-center, prospective, single-arm, phase II study of Osimertinib combined with Aspirin neoadjuvant therapy for resectable, EGFR mutated non-small cell lung cancer (NSCLC). It is mainly aimed at the population of patients with primary IIA- IIIA EGFR sensitive mutations that are intended to be treated with Osimertinib neoadjuvant therapy.",[57,58],"Non Small Cell Lung Cancer","EGFR Gene Mutation",[60,24,18,61,62],"Non-Small Cell Lung Cancer","EGFR-TKI","neoadjuvant therapy","NOT_YET_RECRUITING","2023-09-16",{"date":66,"type":67},"2023-09-21","ACTUAL",{"date":69,"type":51},"2023-09-15",{"date":71,"type":51},"2026-09-01",{"name":5,"class":6}]